Related Experiment Videos
[Propafenone in refractory supraventricular arrhythmias]
Giornale Italiano Di Cardiologia
|May 1, 1984
Summary
Propafenone effectively treats refractory ventricular arrhythmias. This study shows significant reduction in ventricular ectopy and tachycardia with minimal cardiac effects, supporting its use in long-term management.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Context:
- Ventricular arrhythmias pose a significant clinical challenge.
- Refractory cases often require novel therapeutic strategies.
- Propafenone is a Class Ic antiarrhythmic agent.
Purpose:
- To evaluate the efficacy and safety of oral propafenone in patients with ventricular arrhythmias.
- To assess the drug's impact on ventricular tachycardia (VT) and ventricular ectopy (VEB).
- To monitor electrocardiographic changes and inotropic effects.
Summary:
- Propafenone (300-900 mg daily) suppressed VT in 75% and complex VEBs in 60% of patients.
- Total VEBs were reduced by 91.2% in 58.3% of participants.
- Significant PR and QTc interval prolongation occurred only at 900 mg; no negative inotropic effects were observed.
Impact:
- Propafenone demonstrates high efficiency in treating and preventing refractory ventricular arrhythmias.
- The drug is well-tolerated, with minimal adverse cardiac effects.
- Results were sustained over a 5-19 month follow-up period.